Athersys

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of human life. The firm offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

CLEVELAND--(BUSINESS WIRE)---- $ATHX--Topline Phase 2/3 TREASURE data evaluating MultiStem cell therapy for the treatment of ischemic stroke patients in Japan is expected in May.

Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will present a corporate overview at the Locust Walk Stem Cell Conference, April 11, and at the Needham Healthcare Conference, April 13.

Athersys to Participate in Two Upcoming Investor Conferences

Athersys, Inc. (ATHX) CEO Daniel Camardo on Q4 2021 Results - Earnings Call Transcript

CLEVELAND--(BUSINESS WIRE)---- $ATHX #earnings--Dan Camardo, newly appointed Chief Executive Officer of Athersys, shares his initial perspective on the path to commercial success for the Company.

Athersys Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Here is how Athersys, Inc. (ATHX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

Is Athersys, Inc. (ATHX) Stock Outpacing Its Medical Peers This Year?

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4). Stock Option Award Offered to Daniel Camardo, new Chief Executive Officer.

Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys to Host Year-End 2021 Financial Results Call; New CEO, Daniel A. Camardo, and Management to Host Conference Call on March 15, 2022

Athersys to Host Year-End 2021 Financial Results Call

Ebang International Holdings

Gran Tierra Energy

SNDL Inc.

Exicure Inc

Penny stocks under $1 The post 5 Top Penny Stocks To Buy Under $1 On Webull According To Reddit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks To Buy Under $1 On Webull According To Reddit

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ards--Athersys event will provide an understanding of the expected program milestones and why the Company is well-positioned to deliver on its mission.

Athersys to Host a Virtual Presentation on Its MultiStem® Programs

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--New Athersys CEO Dan Camardo brings extensive market launch experience to lead the Company forward on its path to commercialization.

Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive Officer

Company has a robust pipeline in late-stage clinical development largely unknown to investors.

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Athersys Inc (NASDAQ: ATHX) announced that a manuscript reporting data from its MUST-ARDS clinical trial have been published in the peer-reviewed medical journal, Intensive Care Medicine.  MUST-ARDS Phase 1/2 trial evaluated the safety and efficacy of MultiStem (invimestrocel) cell therapy in patients with acute respiratory distress syndrome (ARDS).

Athersys Shares Jump After MultiStem Cell Therapy Data Published In Medical Journal

The stock price of Athersys Inc (NASDAQ: ATHX) increased by over 15% pre-market today. This is why it happened.

Athersys (ATHX) Stock: Why The Price Jumped Today

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Publication of Athersys clinical trial results show MultiStem cell therapy support potential benefits for ARDS patients, including lower mortality.

Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine

I covered Athersys' ischemic stroke trial earlier.

Athersys: COVID-ARDS Is The Company's Most Important Target

Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Athersys, Inc. (ATHX) Upgraded to Buy: Here's Why

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Athersys (ATHX) Stock?

Athersys, Inc. (ATHX) CEO B.J. Lehmann on Q3 2021 Results - Earnings Call Transcript

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Positive topline data for ARDS study announced and countdown begins to the release of pivotal stroke study data for MultiStem cell therapy.

Athersys Reports Third Quarter 2021 Results and Provides Corporate Update

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys reports its partner Healios provided an update regarding its clinical programs for ARDS and ischemic stroke involving MultiStem cell therapy.

Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K.

CLEVELAND, OH--(BUSINESS WIRE)---- $ATHX #CGMesa21--Athersys, a late-stage clinical company developing MultiStem cell therapy, will be participating in two events at the Cell & Gene Meeting on the Mesa.

Athersys to Present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference

Are Options Traders Betting on a Big Move in Athersys (ATHX) Stock?

Positive ARDS Results in Japan should lead to approval and revenues.

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys partner HEALIOS K.K. announces full enrollment of the TREASURE clinical study evaluating MultiStem® cell therapy for stroke patients.

News for Athersys Stock (ATHX)